查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2019692

2026-2034年全球肝素市場規模、佔有率、趨勢和成長分析報告

Global Heparin Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計肝素市場將從 2025 年的 85.4 億美元成長到 2034 年的 113.5 億美元，2026 年至 2034 年的複合年成長率為 3.22%。

由於肝素作為抗凝血劑在醫療領域廣泛應用，全球肝素市場正經歷顯著成長。肝素常用於外科手術、透析和心血管疾病治療，以防止血液凝固。心臟相關疾病發生率的上升和手術數量的增加正在推動市場需求。

推動市場成長要素包括醫療保健支出增加、人口老化以及人們對抗凝血療法的認知不斷提高。製藥公司正加大研發投入，以開發改良配方和替代療法。此外，新興市場醫療保健基礎設施的擴張也促進了市場成長。

預計未來市場將持續成長，這主要得益於藥物研發的進步以及對更安全、更有效的抗凝血劑日益成長的需求。生物相似藥的興起和生產過程的改進將提高產品的供應量。隨著心血管疾病在全球持續增加，肝素市場預計將保持強勁成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球肝素市場：依類型分類

  • 市場分析、洞察與預測
  • 低分子量肝素
  • 超低分子量肝素
  • 未分級肝素

第5章：全球肝素市場：依給藥途徑分類

  • 市場分析、洞察與預測
  • 靜脈
  • 皮下

第6章 全球肝素市場：依應用分類

  • 市場分析、洞察與預測
  • 靜脈血栓栓塞症
  • 心房顫動
  • 腎功能障礙
  • 冠狀動脈疾病
  • 其他

第7章 全球肝素市場：依最終用途分類

  • 市場分析、洞察與預測
  • 門診
  • 住院治療

第8章：全球肝素市場：依來源分類

  • 市場分析、洞察與預測
  • 源自豬
  • 源自牛
  • 其他

第9章 全球肝素市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第10章 競爭格局

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第11章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Pfizer Inc
    • LEO Pharma A/S
    • Dr. Reddy's Laboratories Ltd
    • GlaxoSmithKline Plc
    • Sanofi
    • Aspen Holdings
    • Fresenius SE & Co. KGaA
    • B. Braun Medical Inc
    • Sandoz（Novartis AG）
簡介目錄
Product Code: VMR11217564

The Heparin Market size is expected to reach USD 11.35 Billion in 2034 from USD 8.54 Billion (2025) growing at a CAGR of 3.22% during 2026-2034.

The global heparin market is experiencing significant growth due to its widespread use as an anticoagulant in medical treatments. Heparin is commonly used in surgeries, dialysis, and the treatment of cardiovascular diseases to prevent blood clotting. The increasing prevalence of heart-related conditions and the growing number of surgical procedures are driving market demand.

Key growth drivers include rising healthcare expenditure, increasing aging population, and growing awareness about anticoagulant therapies. Pharmaceutical companies are investing in research to develop improved formulations and alternatives. Additionally, the expansion of healthcare infrastructure in emerging markets is supporting market growth.

Looking ahead, the market is expected to grow with advancements in drug development and increasing demand for safer and more effective anticoagulants. The rise of biosimilars and improved manufacturing processes will enhance product availability. As cardiovascular diseases continue to rise globally, the heparin market will maintain strong growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

  • Low Molecular Weight Heparin
  • Ultra-low Molecular Weight Heparin
  • Unfractionated Heparin

By Route of Administration

  • Intravenous
  • Subcutaneous

By Application

  • Venous Thromboembolism
  • Atrial Fibrillation
  • Renal Impairment
  • Coronary Artery Disease
  • Others

By End-Use

  • Outpatient
  • Inpatient

By Source

  • Porcine
  • Bovine
  • Others

COMPANIES PROFILED

  • Pfizer Inc, LEO Pharma AS, Dr Reddys Laboratories Ltd, GlaxoSmithKline plc, Sanofi, Aspen Holdings, Fresenius SE Co KGaA, B Braun Medical Inc, Sandoz Novartis AG
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL HEPARIN MARKET: BY TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Type
  • 4.2. Low Molecular Weight Heparin Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Ultra-low Molecular Weight Heparin Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Unfractionated Heparin Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL HEPARIN MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Route Of Administration
  • 5.2. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Subcutaneous Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL HEPARIN MARKET: BY APPLICATION 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Application
  • 6.2. Venous Thromboembolism Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Atrial Fibrillation Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Renal Impairment Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.5. Coronary Artery Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL HEPARIN MARKET: BY END-USE 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast End-use
  • 7.2. Outpatient Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Inpatient Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL HEPARIN MARKET: BY SOURCE 2022-2034 (USD MN)

  • 8.1. Market Analysis, Insights and Forecast Source
  • 8.2. Porcine Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.3. Bovine Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL HEPARIN MARKET: BY REGION 2022-2034 (USD MN)

  • 9.1. Regional Outlook
  • 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.2.1 By Type
    • 9.2.2 By Route Of Administration
    • 9.2.3 By Application
    • 9.2.4 By End-use
    • 9.2.5 By Source
    • 9.2.6 United States
    • 9.2.7 Canada
    • 9.2.8 Mexico
  • 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.3.1 By Type
    • 9.3.2 By Route Of Administration
    • 9.3.3 By Application
    • 9.3.4 By End-use
    • 9.3.5 By Source
    • 9.3.6 United Kingdom
    • 9.3.7 France
    • 9.3.8 Germany
    • 9.3.9 Italy
    • 9.3.10 Russia
    • 9.3.11 Rest Of Europe
  • 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.4.1 By Type
    • 9.4.2 By Route Of Administration
    • 9.4.3 By Application
    • 9.4.4 By End-use
    • 9.4.5 By Source
    • 9.4.6 India
    • 9.4.7 Japan
    • 9.4.8 South Korea
    • 9.4.9 Australia
    • 9.4.10 South East Asia
    • 9.4.11 Rest Of Asia Pacific
  • 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.5.1 By Type
    • 9.5.2 By Route Of Administration
    • 9.5.3 By Application
    • 9.5.4 By End-use
    • 9.5.5 By Source
    • 9.5.6 Brazil
    • 9.5.7 Argentina
    • 9.5.8 Peru
    • 9.5.9 Chile
    • 9.5.10 Rest of Latin America
  • 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.6.1 By Type
    • 9.6.2 By Route Of Administration
    • 9.6.3 By Application
    • 9.6.4 By End-use
    • 9.6.5 By Source
    • 9.6.6 Saudi Arabia
    • 9.6.7 UAE
    • 9.6.8 Israel
    • 9.6.9 South Africa
    • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

  • 10.1. Recent Developments
  • 10.2. Company Categorization
  • 10.3. Supply Chain & Channel Partners (based on availability)
  • 10.4. Market Share & Positioning Analysis (based on availability)
  • 10.5. Vendor Landscape (based on availability)
  • 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL HEPARIN INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Company Profiles
    • 11.2.1 Pfizer Inc
    • 11.2.2 LEO Pharma A/S
    • 11.2.3 Dr. Reddy's Laboratories Ltd
    • 11.2.4 GlaxoSmithKline Plc
    • 11.2.5 Sanofi
    • 11.2.6 Aspen Holdings
    • 11.2.7 Fresenius SE & Co. KGaA
    • 11.2.8 B. Braun Medical Inc
    • 11.2.9 Sandoz (Novartis AG)